Results 21 to 30 of about 31,287 (242)

Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study

BMC Rheumatology, 2022
Background This pilot study’s primary aim was to determine if oligoclonal B cell expansion in children with Juvenile Dermatomyositis (JDM) predicts response to Rituximab therapy.
Elisa Ochfeld, Victoria Hans, Wil Marin, Najah Ahsan, Gabrielle Morgan, Lauren M. Pachman, Amer Khojah   +6 more
doaj   +1 more source

Update on rituximab [PDF]

Annals of the Rheumatic Diseases, 2005
Rituximab is a chimeric monoclonal antibody that was developed for the treatment of B cell lymphomas.1 It is directed against the CD20 cell surface molecule.2 CD20 is a tetraspan membrane protein that is present only on B cells, and is expressed initially at the immature B cell stage, remaining until the final differentiation into plasma cells.
openaire   +2 more sources

Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder

Journal of Immunology Research, 2014
We retrospectively analyzed the p.V158F polymorphism of Fcγ-receptor IIIA (FCGR3A, CD16) in patients with PTLD treated with rituximab monotherapy.
Heiner Zimmermann, Theresa Weiland, Jamie P. Nourse, Maher K. Gandhi, Petra Reinke, Ruth Neuhaus, Mohsen Karbasiyan, Barbara Gärtner, Ioannis Anagnostopoulos, Hanno Riess, Ralf U. Trappe, Stephan Oertel   +11 more
doaj   +1 more source

Rituximab for people with multiple sclerosis. [PDF]

, 2021
BACKGROUND Multiple sclerosis (MS) is the most common neurological cause of disability in young adults. Off-label rituximab for MS is used in most countries surveyed by the International Federation of MS, including high-income countries where on-label
Filippini, Graziella, Del Giovane, Cinzia, Filippini G., Del Giovane C., Kruja J., Kruja, Jera   +5 more
core   +1 more source

Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys. [PDF]

PLoS ONE, 2013
The CD20-specific monoclonal antibody rituximab (MabThera(®), Rituxan(®)) is widely used as the backbone of treatment for patients with hematologic disorders. Intravenous administration of rituximab is associated with infusion times of 4-6 hours, and can
Cheng-Ping Mao, Martin R Brovarney, Karim Dabbagh, Herbert F Birnböck, Wolfgang F Richter, Christopher J Del Nagro   +5 more
doaj   +1 more source

Primary vs. Secondary Antibody Deficiency: Clinical Features and Infection Outcomes of Immunoglobulin Replacement [PDF]

, 2014
Secondary antibody deficiency can occur as a result of haematological malignancies or certain medications, but not much is known about the clinical and immunological features of this group of patients as a whole. Here we describe a cohort of 167 patients
Matthew Buckland (589995), Lorena Lorenzo (589997), Matthew Buckland, Dempster, J, Duraisingham Sai S., Longhurst Hilary J., Matthew Buckl, Sai S. Duraisingham, Sofia Grigoriadou (589998), Sai S Duraisingham, Hilary J Longhurst, John Dempster, Dempster John, Grigoriadou Sofia, Duraisingham, SS, Lorenzo, L, Buckland Matthew, Grigoriadou, S, Sofia Grigoriadou, Lorenzo Lorena, Sai S. Duraisingham (589994), Buckland, M, Longhurst, HJ, Lorena Lorenzo, John Dempster (589996), Buckland, MS, Hilary J. Longhurst (589999), Hilary J. Longhurst   +27 more
core   +1 more source

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

, 2010
Rituximab, a monoclonal antibody which targets CD20 on B-cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success a substantial proportion of B-cell lymphomas are unresponsive or develop resistance ...
French, R.R., Johnson, P.W.M., Cox, Kerry L., Chan, Claude H.T., Johnston, David A., Glennie, Martin J., Jarrett, T.C., Glennie, M.J., Verbeek, Sjef, Chan, H.T.C., Dixon, S.V., Mora Vidal, Regina, Wijayaweera, Sahan S., Cragg, Mark S., Lim, Sean H., Dixon, Sandra V., Verbeek, J.S., French, Ruth R., Wijayaweera, S.S., Jarrett, Timothy C., Cragg, M.S., Kim, Hyung J., Kerr, Jonathan P., Vidal, R.M., Johnston, D.A., Lim, S.H., Cox, K.L., Kerr, J.P., Johnson, Peter W.M., Beers, Stephen A., Kim, H., Beers, S.A.   +31 more
core   +1 more source

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey

Pharmaceuticals, 2014
Biologics such as rituximab are an important component of oncology treatment strategies, although access to such therapies is challenging in countries with limited resources.
William H. Baer II, Archana Maini, Ira Jacobs   +2 more
doaj   +1 more source

Hypokalemia after rituximab administration in nephrotic syndrome: two case reports

BMC Nephrology, 2023
Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment for nephrotic syndrome. Hypokalemia is a rare adverse reaction among patients treated with rituximab although there have been extensive reports of acute and chronic adverse ...
Yiyun Song, Lin Ding, Xin An, Yi Zhao, Xianhua Li, Xiangdong Yang, Xiaoyan Xiao   +6 more
doaj   +1 more source

Super‐Refractory Status Epilepticus (SRSE) in a Patient With Compound Heterozygous OPA1 Variants: Case Report and Literature Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Super‐Refractory Status Epilepticus (SRSE) is a rare, life‐threatening neurological emergency with unclear etiology in many cases. Mitochondrial dysfunction, often due to disease‐causing genetic variants, is increasingly recognized as a cause, with each gene producing distinct pathophysiological mechanisms.
Pouria Mohammadi, Lara Basovic, Christopher Michael McGraw   +2 more
wiley   +1 more source